In last trading session, Bicara Therapeutics Inc (NASDAQ:BCAX) saw 0.51 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $10.57 trading at -$1.26 or -10.65% at ring of the bell on the day assigns it a market valuation of $576.31M. That closing price of BCAX’s stock is at a discount of -165.75% from its 52-week high price of $28.09 and is indicating a discount of -5.01% from its 52-week low price of $11.10. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.53 million shares which gives us an average trading volume of 457.21K if we extend that period to 3-months.
Bicara Therapeutics Inc (NASDAQ:BCAX) trade information
Upright in the red during last session for losing -10.65%, in the last five days BCAX remained trading in the red while hitting it’s week-highest on Monday, 03/31/25 when the stock touched $10.57 price level, adding 23.68% to its value on the day. Bicara Therapeutics Inc’s shares saw a change of -39.32% in year-to-date performance and have moved -21.12% in past 5-day. Bicara Therapeutics Inc (NASDAQ:BCAX) showed a performance of -32.89% in past 30-days. Number of shares sold short was 5.05 million shares which calculate 15.48 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 41.5 to the stock, which implies a rise of 74.53% to its current value. Analysts have been projecting 35 as a low price target for the stock while placing it at a high target of 48. It follows that stock’s current price would drop -231.13% in reaching the projected high whereas dropping to the targeted low would mean a loss of -231.13% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 57.59% while estimates for its earnings growth in next 5 years are of 11.91%.
Bicara Therapeutics Inc (NASDAQ:BCAX)’s Major holders
Insiders are in possession of 0.43% of company’s total shares while institution are holding 85.89 percent of that, with stock having share float percentage of 86.26%. Investors also watch the number of corporate investors in a company very closely, which is 85.89% institutions for Bicara Therapeutics Inc that are currently holding shares of the company.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and T. Rowe Price New Horizons Fund, Inc. are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 636.55 shares of worth $6.73 million or 1.17% of the total outstanding shares. The later fund manager was in possession of 589.03 shares on Dec 31, 2024 , making its stake of worth around $6.23 million in the company or a holder of 1.08% of company’s stock.
